Literature DB >> 34059516

Socioeconomic inequality in oral anticoagulation therapy initiation in patients with atrial fibrillation with high risk of stroke: a register-based observational study.

Elin Danielsen Lunde1,2,3, Albert Marni Joensen4, Kirsten Fonager3,5, Søren Lundbye-Christensen2,6, Søren Paaske Johnsen7, Mogens Lytken Larsen3, Gregory Yh Lip8,9, Sam Riahi4,2,3.   

Abstract

OBJECTIVE: The study aimed to examine the association between socioeconomic factors (SEFs) and oral anticoagulation (OAC) therapy and whether it was influenced by changing guidelines. We hypothesised that inequities in initiation of OAC reduced over time as more detailed and explicit clinical guidelines were issued.
DESIGN: Register-based observational study. SETTINGS: All Danish patients with an incident hospital diagnosis of atrial fibrillation (AF), aged ≥30 years old and with high risk of stroke from 1 May 1999 to 2 October 2015 were included. Absolute risk differences (RD) (95% CI) were used to measure the association. PARTICIPANTS: 154 448 patients (mean age 78.2 years, men 47.3%). EXPOSURE: Education, family income and cohabiting status were the SEFs used as exposure. OUTCOME: A prescription of OAC within -30 to +90 days of baseline (incident AF).
RESULTS: During 2002-2007, the crude RD of initiation of OAC for men with high education was 14.9% (12.8 to 16.9). Inequality reduced when new guidelines were published, and in 2013-2016 the crude RD was 5.6% (3.5 to 7.7). After adjusting for age, the RD substantially reduced. The same pattern was seen for cohabiting status, while inequality was smaller and more constant for income.
CONCLUSION: Patients with low income, low education and living alone were associated with lower chance of being initiated with OAC. For education and cohabiting status, the crude difference reduced around 2011, when more detailed clinical guidelines were implemented in Denmark. Our results indicate that new guidelines might reduce inequality in OAC initiation and that new, high-cost drugs increase inequality. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cardiology; social medicine; stroke; thromboembolism

Mesh:

Substances:

Year:  2021        PMID: 34059516     DOI: 10.1136/bmjopen-2021-048839

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  10 in total

1.  Association of Neighborhood Disadvantage and Anticoagulation for Patients with Atrial Fibrillation in the Veterans Health Administration: the REACH-AF Study.

Authors:  Annie McDermott; Nadejda Kim; Leslie R M Hausmann; Jared W Magnani; Chester B Good; Terrence M A Litam; Maria K Mor; Toluwa D Omole; Walid F Gellad; Michael J Fine; Utibe R Essien
Journal:  J Gen Intern Med       Date:  2022-09-23       Impact factor: 6.473

2.  Socioeconomic disparities in use of rhythm control therapies in patients with incident atrial fibrillation: A Finnish nationwide cohort study.

Authors:  Konsta Teppo; Jussi Jaakkola; Fausto Biancari; Olli Halminen; Miika Linna; Jari Haukka; Jukka Putaala; Pirjo Mustonen; Janne Kinnunen; Alex Luojus; Saga Itäinen-Strömberg; Juha Hartikainen; Aapo L Aro; K E Juhani Airaksinen; Mika Lehto
Journal:  Int J Cardiol Heart Vasc       Date:  2022-06-13

3.  Association of income and educational levels with adherence to direct oral anticoagulant therapy in patients with incident atrial fibrillation: A Finnish nationwide cohort study.

Authors:  Konsta Teppo; Jussi Jaakkola; Fausto Biancari; Olli Halminen; Miika Linna; Jari Haukka; Jukka Putaala; Paula Tiili; Ossi Lehtonen; Mikko Niemi; Pirjo Mustonen; Janne Kinnunen; Juha Hartikainen; K E Juhani Airaksinen; Mika Lehto
Journal:  Pharmacol Res Perspect       Date:  2022-06

4.  Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study.

Authors:  Alyaa M Ajabnoor; Salwa S Zghebi; Rosa Parisi; Darren M Ashcroft; Martin K Rutter; Tim Doran; Matthew J Carr; Mamas A Mamas; Evangelos Kontopantelis
Journal:  PLoS Med       Date:  2022-06-07       Impact factor: 11.613

5.  The effect of mental health conditions on the use of oral anticoagulation therapy in patients with atrial fibrillation: the FinACAF study.

Authors:  Jussi Jaakkola; Konsta Teppo; Fausto Biancari; Olli Halminen; Jukka Putaala; Pirjo Mustonen; Jari Haukka; Miika Linna; Janne Kinnunen; Paula Tiili; Aapo L Aro; Juha Hartikainen; K E Juhani Airaksinen; Mika Lehto
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2022-05-05

6.  The nationwide Finnish anticoagulation in atrial fibrillation (FinACAF): study rationale, design, and patient characteristics.

Authors:  Mika Lehto; Olli Halminen; Pirjo Mustonen; Jukka Putaala; Miika Linna; Janne Kinnunen; Elis Kouki; Jussi Niiranen; Juha Hartikainen; Jari Haukka; Kari Eino Juhani Airaksinen
Journal:  Eur J Epidemiol       Date:  2022-01-05       Impact factor: 8.082

7.  American Journal of Preventive Cardiology: Area Deprivation Index and Oral Anticoagulation in New Onset Atrial Fibrillation.

Authors:  Toluwa D Omole; Jianuhi Zhu; William Garrard; Floyd W Thoma; Suresh Mulukutla; Annie McDermott; Brandon M Herbert; Utibe R Essien; Jared W Magnani
Journal:  Am J Prev Cardiol       Date:  2022-04-27

8.  Global Oral Anticoagulation Use Varies by Region in Patients With Recent Diagnosis of Atrial Fibrillation: The GLORIA-AF Phase III Registry.

Authors:  Valentina Bayer; Agnieszka Kotalczyk; Bory Kea; Christine Teutsch; Peter Larsen; Dana Button; Menno V Huisman; Gregory Y H Lip; Brian Olshansky
Journal:  J Am Heart Assoc       Date:  2022-03-04       Impact factor: 6.106

9.  Income and outcomes of patients with incident atrial fibrillation.

Authors:  Fausto Biancari; Konsta Teppo; Jussi Jaakkola; Olli Halminen; Miika Linna; Jari Haukka; Jukka Putaala; Pirjo Mustonen; Janne Kinnunen; Juha Hartikainen; Aapo Aro; Juhani Airaksinen; Mika Lehto
Journal:  J Epidemiol Community Health       Date:  2022-06-15       Impact factor: 6.286

10.  Disparities in oral anticoagulation initiation in patients with schizophrenia and atrial fibrillation: A nationwide cohort study.

Authors:  Anette Arbjerg Højen; Peter Brønnum Nielsen; Sam Riahi; Martin Jensen; Gregory Y H Lip; Torben Bjerregaard Larsen; Mette Søgaard
Journal:  Br J Clin Pharmacol       Date:  2022-04-08       Impact factor: 3.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.